PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO) today reported its financial results for the fourth quarter and year ended December 31, 2006. The Company also reiterated its plans to launch CAPHOSOL® in the U.S. during the first quarter of 2007. CAPHOSOL is an advanced electrolyte solution for the treatment of oral mucositis and dry mouth that is approved in the U.S. as a prescription medical device. CAPHOSOL was in-licensed by Cytogen in October 2006 and represents the Company’s fourth marketed oncology product in the United States.
